Impact of target volume delineation accuracy on locoregional control and survival after postoperative radiotherapy for colorectal cancer

Table 1 Comparison of clinicopathological characteristics between the two groups, n (%)

Characteristic	Accurate target volume group (n = 126)	Inaccurate target volume group (n = 92)	χ2/Z value	P value
Gender			0.428	0.513
Male	78 (61.9)	54 (58.7)
Female	48 (38.1)	38 (41.3)
Age			0.195	0.659
≤ 60 years	68 (54.0)	52 (56.5)
> 60 years	58 (46.0)	40 (43.5)
Age [years, M (range)]	58 (32-78)	60 (35-77)	-0.864	0.388
ECOG score			1.203	0.548
Score 0	52 (41.3)	34 (37.0)
Score 1	62 (49.2)	48 (52.2)
Score 2	12 (9.5)	10 (10.9)
Primary tumor location			0.015	0.903
Rectum	76 (60.3)	56 (60.9)
Colon	50 (39.7)	36 (39.1)
Pathological type			0.003	0.958
Adenocarcinoma	118 (93.7)	86 (93.5)
Mucinous adenocarcinoma	8 (6.3)	6 (6.5)
Pathological differentiation			0.782	0.676
Well differentiated	18 (14.3)	10 (10.9)
Moderately differentiated	86 (68.3)	66 (71.7)
Poorly differentiated	22 (17.5)	16 (17.4)
pT stage			0.621	0.431
T3	94 (74.6)	65 (70.7)
T4	32 (25.4)	27 (29.3)
pN stage			1.847	0.397
N0	38 (30.2)	24 (26.1)
N1	58 (46.0)	38 (41.3)
N2	30 (23.8)	30 (32.6)
Vascular invasion			0.127	0.722
No	84 (66.7)	59 (64.1)
Yes	42 (33.3)	33 (35.9)
Neural invasion			0.009	0.924
No	98 (77.8)	71 (77.2)
Yes	28 (22.2)	21 (22.8)
Margin status			0.583	0.445
Negative	112 (88.9)	78 (84.8)
Positive or close	14 (11.1)	14 (15.2)
Preoperative CEA level			0.152	0.697
Normal	78 (61.9)	54 (58.7)
Elevated	48 (38.1)	38 (41.3)
Preoperative CA19-9 level			0.341	0.559
Normal	94 (74.6)	65 (70.7)
Elevated	32 (25.4)	27 (29.3)
Surgical approach			0.098	0.754
Open	46 (36.5)	32 (34.8)
Laparoscopic	80 (63.5)	60 (65.2)
Neoadjuvant therapy			0.218	0.641
No	98 (77.8)	74 (80.4)
Yes	28 (22.2)	18 (19.6)
Concurrent chemotherapy regimen			0.446	0.504
mFOLFOX6	88 (69.8)	61 (66.3)
Single-agent capecitabine	38 (30.2)	31 (33.7)
Number of chemotherapy cycles			0.528	0.768
≤ 4 cycles	26 (20.6)	21 (22.8)
4-6 cycles	82 (65.1)	58 (63.0)
> 6 cycles	18 (14.3)	13 (14.1)

CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; ECOG: Eastern Cooperative Oncology Group.